{"schema_version":"secwatch.filing_event.v1","accession":"0001649094-26-000041","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2026-08-05T20:07:51+00:00","discovered_at":"2026-08-05T20:09:00.248288+00:00","generated_at":"2026-08-05T20:11:20.304312+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vaxcyte Q2 net loss $284M; VAX-31 OPUS-1 topline data expected Q4 2026","bullets":["Net loss of $284.3M in Q2 2026 vs $166.6M in Q2 2025; R&D expenses rose to $267.9M.","Cash, equivalents and investments $2.5B as of June 30, 2026, up from $2.44B at year-end 2025.","VAX-31 adult Phase 3 OPUS-1 noninferiority trial fully enrolled; topline data due Q4 2026.","VAX-31 infant Phase 2 dose-finding study data expected by end of H1 2027.","Phase 1 study of VAX-A1 (Group A Strep) initiated; topline data expected H2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001649094-26-000041","json":"https://secwatch.observer/filing/0001649094-26-000041.json","markdown":"https://secwatch.observer/filing/0001649094-26-000041.md","text":"https://secwatch.observer/filing/0001649094-26-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000164909426000041/0001649094-26-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000164909426000041/pcvx-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:11:20.304312+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}